BrightPath Biotherapeutics Co

BrightPath Biotherapeutics Co EBIT Margin

The EBIT Margin (Operating Margin) of BrightPath Biotherapeutics Co (4594.T) as of Oct 17, 2026 is -1.54 M %. In the previous year, EBIT Margin (Operating Margin) was -102,464.08 % — a change of 1,404.59% (lower).

EBIT Margin

-1.54 M %

YoY

1,404.59%

Last updated:

EBIT Margin (Operating Margin) of BrightPath Biotherapeutics Co is 2026 -1.54 M % . EBIT Margin (Operating Margin) of BrightPath Biotherapeutics Co was 2025 -102,464.08 % . It decreases by 1,404.59% lower compared to the previous year.

BrightPath Biotherapeutics Co's operating (EBIT) margin stands at -1,541,666.7%, down from -9,614.6% several years earlier.

The BrightPath Biotherapeutics Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-1,087.34 JPY
Jan 1, 2020
-16,171.23 JPY
Jan 1, 2021
-69,201.36 JPY
Jan 1, 2022
-9,614.55 JPY
Jan 1, 2023
-28,099.85 JPY
Jan 1, 2024
-1.60 M JPY
Jan 1, 2025
-102,464.08 JPY
Jan 1, 2026
-1.54 M JPY
The BrightPath Biotherapeutics Co EBIT Margin history
YEAREBIT MarginYoY
-1.54 M %+1,404.59%
-102,464.08 %-93.61%
-1.60 M %+5,609.20%
-28,099.85 %+192.26%
-9,614.55 %-86.11%
-69,201.36 %+327.93%
-16,171.23 %+1,387.23%
-1,087.34 %+140.16%
-452.75 %+115.33%
-210.26 %+74.92%
-120.20 %+100.66%
-59.90 %+1,910.92%
-2.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BrightPath Biotherapeutics Co Stock analysis

What does BrightPath Biotherapeutics Co do? BrightPath Biotherapeutics Co Ltd, headquartered in Chiyoda-ku, Tokyo, operates in the Health Care sector, specializing in biotechnology. The company develops cancer peptide vaccines as part of cancer immunotherapy, focusing on drug discovery, early clinical development, and commercialization of immunotherapeutic drugs in Japan and internationally. It generates revenue through license fees from pharmaceutical companies. Listed on October 22, 2015, the firm employs 32 full-time staff. BrightPath Biotherapeutics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightPath Biotherapeutics Co stock

EBIT Margin (Operating Margin) of BrightPath Biotherapeutics Co is -1.54 M % in 2026.

EBIT Margin (Operating Margin) of BrightPath Biotherapeutics Co changed from -102,464.08 % to -1.54 M %, representing a 1,404.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) BrightPath Biotherapeutics Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s BrightPath Biotherapeutics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — BrightPath Biotherapeutics Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — BrightPath Biotherapeutics Co